November 20, 2024 06:30 AM ESTUpdated 07:06 AM
Startups
Deals
Pharma

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Kyle LaHucik

Senior Reporter

Pfiz­er is en­list­ing an­oth­er Flag­ship start­up to help it cre­ate new obe­si­ty med­i­cines.

Af­ter June’s Pro­Found Ther­a­peu­tics tie-up, Pfiz­er will work with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times